SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)George D. Demetri, Michael C. Heinrich, Jayesh Desai et al.|Journal of Clinical Oncology|2004Cited by 103
Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with <i>KIT</i> and <i>PDGFRA</i> mutation statusMichael C. Heinrich, G. D. Demetri, Jonathan A. Fletcher et al.|Journal of Clinical Oncology|2006Cited by 83
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)George D. Demetri, Michael C. Heinrich, Jayesh Desai et al.|Journal of Clinical Oncology|2004Cited by 46
Correlation of KIT and PDGFRA mutation status with sunitinib activity in imatinib-resistant GISTMichael C. Heinrich, George D. Demetri, Robert G. Maki et al.|Unknown|2006Cited by 0
Data from Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib FailureGeorge D. Demetri, Robert G. Maki, Michael C. Heinrich et al.|Unknown|2023Cited by 0